Arcutis Biotherapeutics Inc (ARQT)
8.875
-0.28
(-3.11%)
USD |
NASDAQ |
May 28, 16:00
8.91
+0.04
(+0.39%)
After-Hours: 20:00
Arcutis Biotherapeutics Cash from Investing (TTM): 43.78M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 43.78M |
December 31, 2023 | 180.23M |
September 30, 2023 | 284.62M |
June 30, 2023 | 41.81M |
March 31, 2023 | 5.255M |
December 31, 2022 | -87.20M |
September 30, 2022 | -105.90M |
June 30, 2022 | 94.83M |
March 31, 2022 | -122.65M |
Date | Value |
---|---|
December 31, 2021 | -75.95M |
September 30, 2021 | -175.34M |
June 30, 2021 | -270.53M |
March 31, 2021 | -99.50M |
December 31, 2020 | -181.82M |
September 30, 2020 | -141.93M |
June 30, 2020 | -29.12M |
March 31, 2020 | -37.38M |
December 31, 2019 | -26.32M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-270.53M
Minimum
Jun 2021
284.62M
Maximum
Sep 2023
-39.06M
Average
-56.67M
Median
Cash from Investing (TTM) Benchmarks
Marinus Pharmaceuticals Inc | 44.28M |
AdaptHealth Corp | -355.60M |
Pfizer Inc | -33.86B |
Heron Therapeutics Inc | -17.56M |
Adverum Biotechnologies Inc | 53.32M |